Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients followed for amyloidosis with proved cardiac injury or strongly suspected:~  * cardiac echography with typical signs of amyloid injury,~ * anatomical result confirming presence of amyloid deposits at cardiac or peripheral level~* Signature of Informed Consent Form,~* Affiliation to a social security system~Exclusion Criteria:~* Patient who suffers from another pathology which could lead cardiac injury (coronary disease, valvular disease, other pathology of deposit),~* Pregnancy and lactating women,~* Absence of effective contraception,~* Irradiating examination performed within the last 12 months or scheduled within the next 12 months,~* Unable patient physically, mentally or legally to provide informed consent,~* Patient under a system of legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET with 18 F-Flutemetamol (Type: EXPERIMENTAL): PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication

Based on this trial design, predict the completion outcome and termination type (if applicable).